UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Photochemical Restoration of Visual Responses in Blind Mice

Neuron (Cambridge, Mass.), 2012-07, Vol.75 (2), p.271-282

2012

Volltextzugriff (PDF)

Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study

Journal of neurology, 2016-06, Vol.263 (6), p.1146-1155

2016

Volltextzugriff (PDF)

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

Frontiers in oncology, 2023-04, Vol.13, p.1161089-1161089

2023

Volltextzugriff (PDF)

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor

Journal for immunotherapy of cancer, 2021-05, Vol.9 (5), p.e002127

2021

Volltextzugriff (PDF)

Dual hyperpolarized [1-13C]pyruvate and [13C]urea magnetic resonance imaging of prostate cancer

Journal of Magnetic Resonance Open, 2024-12, Vol.21, p.100165, Article 100165

2024

Volltextzugriff (PDF)

Hypertension in Young Adults and Subsequent Cardiovascular Disease

JAMA : the journal of the American Medical Association, 2019-04, Vol.321 (13), p.1310

2019

Volltextzugriff (PDF)

Diagnosis and management of neuroendocrine prostate cancer

The Prostate, 2024-04, Vol.84 (5), p.426-440

2024

Volltextzugriff (PDF)

Periprocedural Bridging in Patients with Venous Thromboembolism: A Systematic Review

The American journal of medicine, 2019-06, Vol.132 (6), p.722-732.e7

2019

Volltextzugriff (PDF)

A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer

Journal of clinical oncology, 2024-06, Vol.42 (16_suppl), p.TPS5111-TPS5111

2024

Volltextzugriff (PDF)

Real-World Experience with 177 Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval

Journal of Nuclear Medicine, 2024-05, Vol.65 (5), p.735-739

2024

Volltextzugriff (PDF)

Initial Experience with 68 Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer

Journal of Nuclear Medicine, 2024-01, p.jnumed.123.266390

2024

Volltextzugriff (PDF)

Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5063-5063

2023

Volltextzugriff (PDF)

Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer

The Journal of nuclear medicine (1978), 2024-02, Vol.65 (2), p.199-205

2024

Volltextzugriff (PDF)

Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer

European urology, 2022-02, Vol.81 (2), p.219-221

2022

Volltextzugriff (PDF)

A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Clinical cancer research, 2022-04, Vol.28 (8), p.1531-1539

2022

Volltextzugriff (PDF)

Implementing consultation audio recording applications to improve informed decision-making (IDM) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) eligible for docetaxel

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.103-103

2024

Volltextzugriff (PDF)

Association of HER2 expression in advanced urothelial carcinoma (aUC) and treatment outcomes with immune checkpoint inhibitors and enfortumab vedotin

Journal of clinical oncology, 2024-02, Vol.42 (4_suppl), p.599-599

2024

Volltextzugriff (PDF)

Single-dose 177 Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

The lancet oncology, 2023-11, Vol.24 (11), p.1266

2023

Volltextzugriff (PDF)

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

The lancet oncology, 2023-11, Vol.24 (11), p.1266-1276

2023

Volltextzugriff (PDF)

Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review

Translational andrology and urology, 2021-07, Vol.10 (7), p.3130-3143

2021

Volltextzugriff (PDF)

Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.5032-5032

2023

Volltextzugriff (PDF)

Defining the prevalence of inherited DNA damage repair genetic variants (DDRv) in men with prostate cancer (PCa) detected by PSMA PET

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e17010-e17010

2023

Volltextzugriff (PDF)

Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.532-532

2023

Volltextzugriff (PDF)

Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB)

Journal of clinical oncology, 2023-02, Vol.41 (6_suppl), p.534-534

2023

Volltextzugriff (PDF)

A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC)

Journal of clinical oncology, 2021-05, Vol.39 (15_suppl), p.5043-5043

2021

Volltextzugriff (PDF)

1 – 25 von 46

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(44)
Mit Volltextzugriff
(39)

Publikationsform

Artikel
(46)

Sprache

Englisch
(46)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(21)
Science & Technology
(21)
Humans
(17)
Oncology
(11)
Urology & Nephrology
(11)
Male
(9)
Retrospective Studies
(9)
Bladder Cancer
(8)
Immunotherapy
(8)
Carcinoma, Transitional Cell - Drug Therapy
(6)
Immune Checkpoint Inhibitors
(6)
Metastases
(6)
Treatment Outcome
(6)
Urothelial Carcinoma
(6)
Immune Checkpoint Inhibitors - Therapeutic Use
(5)
Patients
(5)
Aged
(4)
Female
(4)
Metastasis
(4)
Outcomes
(4)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Photochemical Restoration of Visual Responses in Blind Mice

Quantification of normal-appearing white matter tract integrity in multiple sclerosis: a diffusion kurtosis imaging study

Somatic alterations of TP53 and MDM2 associated with response to enfortumab vedotin in patients with advanced urothelial cancer

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor

Dual hyperpolarized [1-13C]pyruvate and [13C]urea magnetic resonance imaging of prostate cancer

Hypertension in Young Adults and Subsequent Cardiovascular Disease

Diagnosis and management of neuroendocrine prostate cancer

Periprocedural Bridging in Patients with Venous Thromboembolism: A Systematic Review

A phase 1/2 study of ONCT-534, a dual-action androgen receptor inhibitor (DAARI), in patients with metastatic castration-resistant prostate cancer

Real-World Experience with 177 Lu-PSMA-617 Radioligand Therapy After Food and Drug Administration Approval

Initial Experience with 68 Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer

Early changes of PSMA PET signal after initiation of androgen receptor signaling inhibitors in mCRPC: An international multicenter retrospective study

Initial Experience with 68Ga-FAP-2286 PET Imaging in Patients with Urothelial Cancer

Hyperpolarized 1-[13C]-Pyruvate Magnetic Resonance Imaging Detects an Early Metabolic Response to Immune Checkpoint Inhibitor Therapy in Prostate Cancer

A Phase Ib/II Study of the CDK4/6 Inhibitor Ribociclib in Combination with Docetaxel plus Prednisone in Metastatic Castration-Resistant Prostate Cancer

Implementing consultation audio recording applications to improve informed decision-making (IDM) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) eligible for docetaxel

Association of HER2 expression in advanced urothelial carcinoma (aUC) and treatment outcomes with immune checkpoint inhibitors and enfortumab vedotin

Single-dose 177 Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

Single-dose 177Lu-PSMA-617 followed by maintenance pembrolizumab in patients with metastatic castration-resistant prostate cancer: an open-label, dose-expansion, phase 1 trial

Prostate-specific membrane antigen (PSMA)-based imaging in localized and advanced prostate cancer: a narrative review

Sequential metastasis-directed therapy (MDT) for oligometastatic prostate cancer (Oligo PCa) assessed by PET-based imaging

Defining the prevalence of inherited DNA damage repair genetic variants (DDRv) in men with prostate cancer (PCa) detected by PSMA PET

Association of biomarkers and outcomes in patients (pts) with metastatic urothelial carcinoma (mUC) treated with immune checkpoint inhibitors (ICIs)

Association of biomarkers and response to immune checkpoint inhibitors (ICIs) in patients with metastatic urothelial carcinoma (mUC) with high and low tumor mutation burden (TMB)

A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC)

Suchergebnisse filtern